Doug Miller
Professor
Academic Appointment(s)
Medical College of Georgia
Department of Medicine: Cardiology
Medical College of Georgia
Department of Population Health Science: Health Econ Modeling
Medical College of Georgia
Department of Radiology and Imaging
- DDMILLER@augusta.edu
- (762) 375-5223
- 937 15th Street, Augusta, GA 30912
Education
-
MBA, Intl Business
St Louis University, 1999
-
MDCM, Medicine
McGill University, 1978
Certifications
Awards & Honors
-
2023 Distinguished Fellow
National Academy of Practice (NAP), 2023
-
Castle-Connelly Top Docs
Castle-Connelly, 2022
Courses Taught Most Recent Academic Year
-
GMED 5000
Basic Clerkship GMED
-
RCAR 5000
Cardiology
-
GMED 5017
Cardiology Consult
-
GMED 5011
Medicine Sub-I
-
MEDI 6110
Patient Centered Learning 1
-
MEDI 6310
Patient Centered Learning 3
-
MEDI 6210
Patient Centered Learning 2
-
MEDI 6510
PCL Adv Clerkship
Teaching Interests
Dr. Miller is actively teaching MCG medical students and residents on a weekly basis, with emphasis on patient centered learning and on complex cardiovascular care management. He also trains the Cardiovascular fellows in advanced cardiac imaging and cardiovascular disease prevention strategies.
Scholarship
Selected Recent Publications
- Beneath the Skinfolds: Diagnostic Hope for the Obese and Formerly Obese. , 2025
Journal Article, Academic Journal
- Disease Registries as a National Asset: The Canadian CAPER, 2025
Journal Article, Academic Journal
- Multimodal Imaging of a Sudden Cardiac Death Survivor from El Salvador, 2025
Journal Article, Academic Journal
- Leveraging Medical Licensure for Safer Artificial Intelligence Use in Health Care, 2025
Journal Article, Academic Journal
- The Calculated Uncertainty of Scientific Discovery: From Maths to Deep Maths, 2023
Book, Chapter in Scholarly Book-New
Research Interests
Dr. Miller is actively pursuing clinical translational research on patients with common and rare cardiovascular conditions, including acute coronary syndromes (ACS), multimodal imaging of infectious and inflammatory cardiomyopathies, and reducing inflammation in cardiometabolic syndromes. He is the principle investigator (PI) of a phase-3 multi-center clinical trial (DAL-302) using genetic markers to guide initiating new drug treatment to reduce the risk of recurrent heart attack in ACS patients (precision medicine).
